December 13, 2024
With the deadline for submissions just around the corner, Jamie Justice, Executive Director of XPRIZE HealthSpan, explains to researchers still on the fence why they should contact her team now but also why missing the deadline is not the end of the world. XPRIZE Foundation has been making history for 30 years with dozens of...
December 12, 2024
Crypto investor and founder Will Harborne will lead a new enterprise aimed at funding and supporting groundbreaking longevity technologies. From crypto to longevity The burgeoning field of longevity biotech is about to have a new player. Like many recent enterprises, such as Brian Armstrong’s NewLimit, this one is driven by someone coming from the crypto...
December 03, 2024
I first met Dr. Mehmood Khan in 2022 at the inaugural Longevity Summit Dublin, where organizers Aubrey de Grey and Martin O’Dea made a bold decision to include policy and advocacy discussions alongside the traditional focus on longevity research. Like many others in the audience, I was captivated by the forceful, engaging, and compelling one-man...
June 10, 2024
Hevolution, the Saudi-funded healthspan non-profit behemoth, has been around for about two years, and it hasn’t been wasting any time, funding research and investing in biotech companies. With its yearly budget touching 1 billion dollars, Hevolution is the biggest non-profit donor and one of the most important players in this field today. Hevolution touts a...
March 22, 2023
2021 marked one of the biggest years in longevity financing, with 2022 following closely behind, according to a report by Longevity.Technology. Over the past ten years, the industry has grown in financing from $500 million in 2013 to a peak of $6.2 billion (2021). Despite taking a dip in 2022, investment in longevity appears to...
August 01, 2022
Preventing the dysfunction of natural killer (NK) cells may be a promising area to explore in the fight against cellular senescence. Researchers are hoping to define the correlation between the increase in senescent cells and the onset or worsening of disease in humans to develop successfully tested therapies that intercept and slow down the process....